levofloxacin has been researched along with acarbose in 6 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (acarbose) | Trials (acarbose) | Recent Studies (post-2010) (acarbose) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 131 | 0 | 122 |
| 4,346 | 581 | 2,209 | 118 | 0 | 86 |
| Protein | Taxonomy | levofloxacin (IC50) | acarbose (IC50) |
|---|---|---|---|
| Alpha-amylase | Acarus siro | 3.8 | |
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | 2 | |
| Pancreatic alpha-amylase | Sus scrofa (pig) | 4.3108 | |
| Alpha-amylase 1A | Homo sapiens (human) | 0.996 | |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | 5 | |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | 2 | |
| D(3) dopamine receptor | Rattus norvegicus (Norway rat) | 2 | |
| Oligo-1,6-glucosidase IMA1 | Saccharomyces cerevisiae S288C | 9.37 | |
| Probable maltase-glucoamylase 2 | Homo sapiens (human) | 2 | |
| Chain A, Cyclomaltodextrin glucanotransferase | Bacillus sp. 1011 | 5600 | |
| Sucrase-isomaltase, intestinal | Rattus norvegicus (Norway rat) | 1.97 | |
| Lysosomal alpha-glucosidase | Rattus norvegicus (Norway rat) | 1.3892 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
1 review(s) available for levofloxacin and acarbose
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for levofloxacin and acarbose
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |